[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,847
  • Shares Outstanding, K 10,940
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,230 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta 0.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.98
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.91
  • Most Recent Earnings $-0.06 on 03/24/26
  • Next Earnings Date 08/10/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 1
  • High Estimate $-0.18
  • Low Estimate $-0.18
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) +55.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8404 +13.15%
on 05/18/26
1.2800 -25.71%
on 04/20/26
-0.2291 (-19.42%)
since 04/17/26
3-Month
0.8404 +13.15%
on 05/18/26
1.4100 -32.56%
on 03/17/26
-0.2091 (-18.03%)
since 02/19/26
52-Week
0.8404 +13.15%
on 05/18/26
2.4500 -61.19%
on 07/10/25
-1.2491 (-56.78%)
since 05/19/25

Most Recent Stories

More News
BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase

SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 0.9509 (+5.64%)
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results

SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 0.9509 (+5.64%)
BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026

SUNNYVALE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 0.9509 (+5.64%)
BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways

SUNNYVALE, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 0.9509 (+5.64%)
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3Dâ„¢ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures

SUNNYVALE, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

BCDA : 0.9509 (+5.64%)
BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure

SUNNYVALE, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

BCDA : 0.9509 (+5.64%)
BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP® System in Ischemic Heart Failure

SUNNYVALE, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

BCDA : 0.9509 (+5.64%)
BioCardia Reports 2025 Business Highlights and Financial Results

SUNNYVALE, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc.  [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 0.9509 (+5.64%)
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026

SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 0.9509 (+5.64%)
BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA

SUNNYVALE, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- BioCardia ® , Inc. [NASDAQ: BCDA] , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...

BCDA : 0.9509 (+5.64%)

Business Summary

BioCardia Inc. is engaged in developing regenerative biologic therapies to treat cardiovascular disease. The company's product candidate consists of CardiAMP(TM), CardiALLO(TM) and Helix Biotherapeutic Delivery System(TM) in clinical development stage. BioCardia Inc. is headquartered in San Carlos, California....

See More

Key Turning Points

3rd Resistance Point 1.0516
2nd Resistance Point 1.0035
1st Resistance Point 0.9772
Last Price 0.9509
1st Support Level 0.9028
2nd Support Level 0.8547
3rd Support Level 0.8284

See More

52-Week High 2.4500
Fibonacci 61.8% 1.8351
Fibonacci 50% 1.6452
Fibonacci 38.2% 1.4553
Last Price 0.9509
52-Week Low 0.8404

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.